Last reviewed · How we verify

valsartan, fluvastatin — Competitive Intelligence Brief

valsartan, fluvastatin (valsartan, fluvastatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ARB/statin combination. Area: Cardiovascular.

marketed ARB/statin combination Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

valsartan, fluvastatin (valsartan, fluvastatin) — Novartis. This combination reduces blood pressure by blocking angiotensin II receptors (valsartan) and lowers cholesterol by inhibiting HMG-CoA reductase (fluvastatin).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
valsartan, fluvastatin TARGET valsartan, fluvastatin Novartis marketed ARB/statin combination Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase
Irbesartan/atorvastatin fixed dose combination Irbesartan/atorvastatin fixed dose combination Sanofi marketed ARB/statin combination Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ARB/statin combination class)

  1. Novartis · 1 drug in this class
  2. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). valsartan, fluvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-fluvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: